Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives

The autoimmune polyglandular syndrome is a sequential chain of autoimmune events. Whenever diagnosed, the clinician's target should be induction of remission and if possible hindering its progression especially if associated with refractory vitiligo, resistant Grave's, or unexplained hyper...

Descripción completa

Detalles Bibliográficos
Autores principales: Allam, Magdy Mohamed, Elzawawy, Hanaa Tarek Hussein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230650/
https://www.ncbi.nlm.nih.gov/pubmed/30455916
http://dx.doi.org/10.1002/ccr3.1827
_version_ 1783370119886405632
author Allam, Magdy Mohamed
Elzawawy, Hanaa Tarek Hussein
author_facet Allam, Magdy Mohamed
Elzawawy, Hanaa Tarek Hussein
author_sort Allam, Magdy Mohamed
collection PubMed
description The autoimmune polyglandular syndrome is a sequential chain of autoimmune events. Whenever diagnosed, the clinician's target should be induction of remission and if possible hindering its progression especially if associated with refractory vitiligo, resistant Grave's, or unexplained hyperglycemia in T1DM. Azathioprine could be used for induction of remission in autoimmune polyglandular syndrome type three especially with vitiligo and autoimmune thyroiditis.
format Online
Article
Text
id pubmed-6230650
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62306502018-11-19 Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives Allam, Magdy Mohamed Elzawawy, Hanaa Tarek Hussein Clin Case Rep Case Reports The autoimmune polyglandular syndrome is a sequential chain of autoimmune events. Whenever diagnosed, the clinician's target should be induction of remission and if possible hindering its progression especially if associated with refractory vitiligo, resistant Grave's, or unexplained hyperglycemia in T1DM. Azathioprine could be used for induction of remission in autoimmune polyglandular syndrome type three especially with vitiligo and autoimmune thyroiditis. John Wiley and Sons Inc. 2018-10-02 /pmc/articles/PMC6230650/ /pubmed/30455916 http://dx.doi.org/10.1002/ccr3.1827 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Allam, Magdy Mohamed
Elzawawy, Hanaa Tarek Hussein
Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives
title Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives
title_full Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives
title_fullStr Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives
title_full_unstemmed Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives
title_short Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives
title_sort induction of remission in autoimmune polyglandular syndrome type three (aps iii): an old drug with new perspectives
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230650/
https://www.ncbi.nlm.nih.gov/pubmed/30455916
http://dx.doi.org/10.1002/ccr3.1827
work_keys_str_mv AT allammagdymohamed inductionofremissioninautoimmunepolyglandularsyndrometypethreeapsiiianolddrugwithnewperspectives
AT elzawawyhanaatarekhussein inductionofremissioninautoimmunepolyglandularsyndrometypethreeapsiiianolddrugwithnewperspectives

Ejemplares similares